Clinical Trial Update: Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the combination of ruxolitinib phosphate and decitabine in patients with relapsed or refractory or post-myeloproliferative acute myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Myeloproliferative Neoplasm

Drugs mentioned

• Decitabine (Decitabine)
• Ruxolitinib phosphate (ruxolitinib phosphate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-15